Our study delineates T cells as a reliable biomarker for evaluating VOCs‐induced lung diseases, provides a novel insight into immunological mechanisms from in situ lung and distal BM hematopoiesis, and offers potential targets (i.e., IL‐6 and IL‐17A) for therapeutic intervention of VOCs‐associated obstructive lung diseases. This evidence concerns the gene IL17A and lung disorder.